




RealRate

PHARMACEUTICAL 2021

Zymeworks Inc.
Rank 175 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Zymeworks Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Zymeworks Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is -85%, being 270% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 455,076 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 17,319 |
| Liabilities, Current | 85,666 |
| Liabilities, Non-Current | 8,669 |
| Other Assets | 53,796 |
| Other Compr. Net Income | 0 |
| Other Expenses | 429 |
| Other Liabilities | 34,119 |
| Other Net Income | 7,345 |
| Property and Equipment | 12,185 |
| Research and Development | 168,534 |
| Revenues | 38,951 |
| Selling, General and Administrative Expense | 57,885 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 538,376 |
| Liabilities | 128,454 |
| Expenses | 226,848 |
| Stockholders Equity | 409,922 |
| Net Income | -180,552 |
| Comprehensive Net Income | -180,552 |
| Economic Capital Ratio | -85% |